Trump Officials Plan to Test New Medicare Drug Pricing Rules

A new regulatory pilot project from the US Medicare and Medicaid Service Centers is examined in the White House budget office, which shows that the Trump administration is trying to take regulatory action against drug producers even if it makes an agreement with individual companies.

There is no detail about the policy that the CMS plans to test, including the pilot, which is to protect the US Medicare against the increasing drug costs ”, including which drugs or companies can be affected. Regulatory pilot projects help the government to determine whether a new regulation will save money and allow them to try the rules before applying them extensively.

The proposed regulation is the agency’s second movement for new rules on drug prices; Another was released on September 25th. During the first management, President Donald Trump watched pilot programs to reduce what Medicare paid for drug prices. The pharmaceutical industry has decisively opposed these initiatives.

Medicare is the US government’s health insurance for elderly adults and the largest drug buyer in the country.

New rules can put a damper on Wall Street’s enthusiasm for drug producers. Pharmaceutical stocks, at the beginning of this week at the oval office of Pfizer Inc. After a jumping activity, it is prepared for the best weeks in 16 years and signed an agreement that the company signed an agreement that allows the company to escape from harder tariffs.

In exchange for getting rid of tariffs, Pfizer has committed to lowering prices in the Medicaid program for low -income and disabled adults, a relatively much smaller part of his income. The agreement was seen as a plan for other companies who wanted to adapt to the administration. These negotiations continue because there is a threat of regulatory action.

This article was created from an automatic news agency feeding without changing the text.